Dihexa for Sleep
Investigational orally active angiotensin-IV-derived peptidomimetic studied preclinically as a hepatocyte growth factor (HGF) potentiator with synaptogenic effects. No human data; educational use only.
Why Dihexa for sleep?
Evidence is preclinical only; there are no human clinical trials of dihexa. Importantly, the foundational 2014 paper describing its HGF/c-Met mechanism (Benoist CC et al., J Pharmacol Exp Ther) has since been RETRACTED, which further weakens the evidence base. A related prodrug (fosgonimeton) was studied in humans but did not establish efficacy. All use is investigational and educational only; efficacy and safety in humans are unproven.
Sleep context: Modulating sleep architecture, slow-wave sleep depth, and circadian regulation. Dihexa fits this goal because its category (Cognitive) and benefit profile align with the underlying mechanism.
Benefits relevant to sleep
- Investigational interest in neurodegeneration research (no proven human benefit)
Reference dosing by bodyweight
Anchored to the most-cited research dose (250 mcg @ 75 kg). Reference only.
| Bodyweight band | Reference dose range |
|---|---|
| <60 kg / <132 lb | 156–211 mcg |
| 60–75 kg / 132–165 lb | 191–259 mcg |
| 75–90 kg / 165–198 lb | 234–316 mcg |
| 90–105 kg / 198–231 lb | 276–374 mcg |
| >105 kg / >231 lb | 319–431 mcg |
Side effects to weigh against sleep benefit
- Not established in humans (no clinical trials)
- Theoretical oncologic risk from c-Met pathway activation
Educational use only
This calculator is provided for research and educational purposes. Outputs are derived from the values you enter. Always verify your math and consult a licensed physician before acting on any result.